A Phase 1 Dose Escalation Study of IPI-493
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Ross, MD
Infinity Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Premiere Oncology, Arizona
Scottsdale, Arizona, United States
- San Diego Pacific Oncology and Hematology Associates
Encinitas, California, United States
- Premiere Oncology, California
Santa Monica, California, United States
- Univeristy of Colorado Health Science Center
Aurora, Colorado, United States
- Mary Crowley Cancer Research Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 31 Jul 2011
- Completion
- 31 Jul 2011
- Last update posted
- 15 Apr 2015
- Registered enrollment
- 53
- Registry id
- NCT00724425
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.